Trius To Present At Future Leaders Conference

SAN DIEGO, April 2, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, April 5 th at 9:00 a.m. Eastern Time at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated Investigational New Drug (IND) enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. For more information, visit www.triusrx.com .
CONTACT: Public Relations Contact:         Laura Kempke/Andrew Law at MSLGROUP         trius@mslgroup.com         781-684-0770                  Investor Relations Contact:         Stefan Loren at Westwicke Partners, LLC         sloren@westwicke.com         443-213-0507

If you liked this article you might like

Cramer's 'Mad Money' Recap: Disciplined Investors Rule

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Cramer Quick Take: What's Next for Biotech?

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys